Salvage Treatment for Recurrent Oral Cancer

  • Mark D. DeLacureEmail author
  • Nicholas J. Sanfilippo


The surgical treatment of recurrent or previously treated malignancies of the oral cavity presents one of the greatest challenges known to the head and neck surgeon and reconstructive oncologist. These problems are faced with unfortunate frequency and bring oft-devastating functional cost along with the very real threat of death from uncontrolled locoregional disease. The “successful” (long-term locoregional control, effective palliation, the occasional cure) treatment of these cases requires technical expertise and judgment known only to the most experienced head and neck surgeon. Despite this, treatment failure is common and humbling.


Oral Cavity Radiat Oncol Biol Phys Late Toxicity Free Tissue Transfer Oral Tongue 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23:3562.CrossRefPubMedGoogle Scholar
  2. 2.
    Stewart JS, Cohen EE, Licitra L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol. 2009;27:1864.CrossRefPubMedGoogle Scholar
  3. 3.
    Machiels J, Haddad RI, Fayette J, et al. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol. 2015;16:583–94.CrossRefPubMedGoogle Scholar
  4. 4.
    Seiwert TY, Haddad RI, Gupta S, et al. Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort. J Clin Oncol. 2015;33(Suppl; abstr LBA6008).Google Scholar
  5. 5.
    Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116.CrossRefPubMedGoogle Scholar
  6. 6.
    Pajwani L. Nivloumab may be “game-changer” in head & neck cancer. Onc Live. 2016;17(5):33, 03.16.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.Department of Otolaryngology-Head and Neck Surgery, Plastic and Reconstructive Surgery, and NeurosurgeryNew York UniversityNew YorkUSA
  2. 2.Department of Radiation OncologyNYU Cancer Institute, New York UniversityNew YorkUSA

Personalised recommendations